Biotech ETFs Vs. The Coronavirus

While much of the stock market has fallen victim to coronapocalypse, there were a handful of virus-resistant stocks that fared better. On this coronavirus-themed episode of Trillions, Eric and Joel dive into the world of niche biotech ETFs with Paul Yook and Ryan Cinalli of LifeSci Index Partners, who have launched two biotech ETFs (tickers BBP and BBC) and are currently working on a third (GERM).